BACKGROUND: Early invasive electrical stimulation studies suggested that enhancement of cerebellar vermal activity might prove valuable in symptomatic treatment of refractory neuropsychiatric diseases via modulation of emotion and affect. This proof of principle study aimed to test this hypothesis using noninvasive brain stimulation, and to explore the safety of this protocol in schizophrenia. METHODS: Eight treatment-refractory patients with schizophrenia underwent ten sessions of intermittent theta burst stimulation (TBS) to the cerebellar vermis using MRI-guided transcranial magnetic stimulation (TMS). Assessments included side effect questionnaires, cardiovascular monitoring, psychiatric evaluations and comprehensive neuropsychological testing before and after TBS and at one-week follow-up. RESULTS: Overall, TBS was tolerated well with mild side effects primarily comprising neck pain and headache. No serious adverse events occurred. Diastolic blood pressure (BP) showed mild decreases for five minutes post-TBS; no significant changes were detected for systolic BP or pulse. PANSS negative subscale showed significant improvements following TBS and during the follow-up. Calgary Depression Scale and self-report visual analog scales for Happiness and Sadness pointed to significant mood elevation. Neuropsychological testing revealed significantly fewer omissions in working memory and interference conditions of a Continuous Performance Test, a longer spatial span and better delay organization on the Rey-Osterrieth Complex Figure during follow-up. No significant worsening in psychiatric or neuropsychological measures was detected. CONCLUSIONS: Theta burst stimulation of the cerebellar vermis is safe and well-tolerated, while offering the potential to modulate affect, emotion and cognition in schizophrenia. Future randomized, sham-stimulation controlled studies are warranted to support the clinical efficacy of this technique.
BACKGROUND: Early invasive electrical stimulation studies suggested that enhancement of cerebellar vermal activity might prove valuable in symptomatic treatment of refractory neuropsychiatric diseases via modulation of emotion and affect. This proof of principle study aimed to test this hypothesis using noninvasive brain stimulation, and to explore the safety of this protocol in schizophrenia. METHODS: Eight treatment-refractory patients with schizophrenia underwent ten sessions of intermittent theta burst stimulation (TBS) to the cerebellar vermis using MRI-guided transcranial magnetic stimulation (TMS). Assessments included side effect questionnaires, cardiovascular monitoring, psychiatric evaluations and comprehensive neuropsychological testing before and after TBS and at one-week follow-up. RESULTS: Overall, TBS was tolerated well with mild side effects primarily comprising neck pain and headache. No serious adverse events occurred. Diastolic blood pressure (BP) showed mild decreases for five minutes post-TBS; no significant changes were detected for systolic BP or pulse. PANSS negative subscale showed significant improvements following TBS and during the follow-up. Calgary Depression Scale and self-report visual analog scales for Happiness and Sadness pointed to significant mood elevation. Neuropsychological testing revealed significantly fewer omissions in working memory and interference conditions of a Continuous Performance Test, a longer spatial span and better delay organization on the Rey-Osterrieth Complex Figure during follow-up. No significant worsening in psychiatric or neuropsychological measures was detected. CONCLUSIONS: Theta burst stimulation of the cerebellar vermis is safe and well-tolerated, while offering the potential to modulate affect, emotion and cognition in schizophrenia. Future randomized, sham-stimulation controlled studies are warranted to support the clinical efficacy of this technique.
Authors: Vincenzo Di Lazzaro; Fabio Pilato; Paolo Profice; Federico Ranieri; Gabriella Musumeci; Lucia Florio; Ettore Beghi; Giovanni Frisullo; Fioravante Capone; Mario Sabatelli; Pietro A Tonali; Michele Dileone Journal: Neurosci Lett Date: 2009-08-12 Impact factor: 3.046
Authors: Steven G Potkin; Gustavo Alva; Kirsten Fleming; Ravi Anand; David Keator; Danilo Carreon; Michael Doo; Yi Jin; Joseph C Wu; James H Fallon Journal: Am J Psychiatry Date: 2002-02 Impact factor: 18.112
Authors: M S George; Z Nahas; M Molloy; A M Speer; N C Oliver; X B Li; G W Arana; S C Risch; J C Ballenger Journal: Biol Psychiatry Date: 2000-11-15 Impact factor: 13.382
Authors: Mario Manto; James M Bower; Adriana Bastos Conforto; José M Delgado-García; Suzete Nascimento Farias da Guarda; Marcus Gerwig; Christophe Habas; Nobuhiro Hagura; Richard B Ivry; Peter Mariën; Marco Molinari; Eiichi Naito; Dennis A Nowak; Nordeyn Oulad Ben Taib; Denis Pelisson; Claudia D Tesche; Caroline Tilikete; Dagmar Timmann Journal: Cerebellum Date: 2012-06 Impact factor: 3.847
Authors: Xavier Guell; Anila M D'Mello; Nicholas A Hubbard; Rachel R Romeo; John D E Gabrieli; Susan Whitfield-Gabrieli; Jeremy D Schmahmann; Sheeba Arnold Anteraper Journal: Cereb Cortex Date: 2020-04-14 Impact factor: 5.357